Your browser is no longer supported. Please, upgrade your browser.
Settings
THTX Theratechnologies Inc. daily Stock Chart
THTX [NASD]
Theratechnologies Inc.
Index- P/E- EPS (ttm)- Insider Own1.45% Shs Outstand77.01M Perf Week-3.21%
Market Cap185.60M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float76.07M Perf Month9.05%
Income- PEG- EPS next Q- Inst Own16.34% Short Float1.53% Perf Quarter6.64%
Sales65.39M P/S2.84 EPS this Y- Inst Trans- Short Ratio3.89 Perf Half Y-14.54%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-43.92%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.33 - 4.52 Perf YTD-26.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.90% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low80.45% ATR0.14
Employees42 Current Ratio- Sales Q/Q9.90% Oper. Margin- RSI (14)57.94 Volatility3.15% 6.05%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.11 Prev Close2.41
ShortableYes LT Debt/Eq- EarningsJul 15 BMO Payout- Avg Volume299.64K Price2.40
Recom- SMA202.85% SMA5013.06% SMA200-5.76% Volume26,878 Change-0.41%
Jul-30-20 07:30AM  
Jul-23-20 04:01PM  
Jul-18-20 10:31AM  
Jul-16-20 12:23PM  
Jul-15-20 10:30PM  
07:30AM  
06:30AM  
Jul-07-20 07:30AM  
Jul-06-20 07:30AM  
Jun-22-20 07:30AM  
May-15-20 07:30AM  
May-12-20 07:30AM  
Apr-27-20 07:30AM  
Apr-16-20 03:23PM  
07:30AM  
Apr-14-20 07:30AM  
06:30AM  
Mar-31-20 07:30AM  
Mar-11-20 12:00PM  
Mar-02-20 08:00AM  
Feb-27-20 08:14AM  
Feb-25-20 07:30AM  
06:30AM  
Feb-18-20 08:00AM  
Feb-04-20 07:30AM  
Dec-19-19 09:06AM  
Dec-13-19 07:30AM  
Oct-17-19 02:42PM  
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.